Impact of prior treatment on CAR T-cell outcome in adult ALL
David I Marks, Anna Z Castleton · 2024
Read Impact of prior treatment on CAR T-cell outcome in adult ALL by David I Marks, Anna Z Castleton (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11707415.txt.
Description
David Marks and Anna Castleton comment on whether earlier drug exposure poisons the results of a powerful cell therapy for leukemia. The therapy engineers a patient's own T cells to hunt the cancer. A study they discuss followed 189 adults with relapsed or stubborn acute lymphoblastic leukemia. Over half had first received inotuzumab, an antibody-drug that targets the same disease.
Patients with that prior exposure did worse after cell therapy. The commentators argue the gap likely reflects who gets the drug, patients with harsher disease, rather than harm done by the drug itself. Plausible biological routes for harm exist, which is why the question mattered. A British study of a sister therapy found a similar pattern. The piece weighs selection effects against drug effects and urges care in reading the numbers.
Catalog record
| CREATOR | David I Marks, Anna Z Castleton |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |